A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome

Arbaclofen in fragile X syndrome: results of phase 3 trials

(2017) Elizabeth Berry-Kravis et al.   Journal of Neurodevelopmental Disorders

A randomized double-blind, placebo-controlled trial of ganaxolone in children and adolescents with fragile X syndrome

(2017) Andrew Ligsay et al.   Journal of Neurodevelopmental Disorders

The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABA A receptors

(2017) T. Bakas et al.   PHARMACOLOGICAL RESEARCH

Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial

(2016) Orrin Devinsky et al.   LANCET NEUROLOGY

Endocannabinoid-mediated improvement on a test of aversive memory in a mouse model of fragile X syndrome

(2015) Mei Qin et al.   BEHAVIOURAL BRAIN RESEARCH

Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder

(2015) Reymundo Lozano et al.   CURRENT PHARMACEUTICAL DESIGN

Fatty Acid-binding Proteins (FABPs) Are Intracellular Carriers for Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD)

(2015) Matthew W. Elmes et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Endocannabinoid-mediated retrograde modulation of synaptic transmission

(2014) Takako Ohno-Shosaku et al.   CURRENT OPINION IN NEUROBIOLOGY

The Roles of FMRP-Regulated Genes in Autism Spectrum Disorder: Single- and Multiple-Hit Genetic Etiologies

(2013) Julia Steinberg et al.   AMERICAN JOURNAL OF HUMAN GENETICS

The challenges of clinical trials in fragile X syndrome

(2013) Sébastien Jacquemont et al.   PSYCHOPHARMACOLOGY

Psychometric evaluation of a visual analog scale for the assessment of anxiety

(2012) Valerie SL Williams et al.   Health and Quality of Life Outcomes

Endocannabinoid Signaling and Synaptic Function

(2012) Pablo E. Castillo et al.   NEURON

Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia

(2012) F M Leweke et al.   Translational Psychiatry

Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients

(2011) Mateus M Bergamaschi et al.   NEUROPSYCHOPHARMACOLOGY

Cannabidiol bioavailability after nasal and transdermal application: effect of permeation enhancers

(2010) Kalpana S. Paudel et al.   DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY

Clinical assessment of DSM-IV anxiety disorders in fragile X syndrome: prevalence and characterization

(2010) Lisa Cordeiro et al.   Journal of Neurodevelopmental Disorders

Enhanced Endocannabinoid Signaling Elevates Neuronal Excitability in Fragile X Syndrome

(2010) L. Zhang et al.   JOURNAL OF NEUROSCIENCE

FAAH and anandamide: is 2-AG really the odd one out?

(2008) Vincenzo Di Marzo et al.   TRENDS IN PHARMACOLOGICAL SCIENCES